key: cord-0737298-onnurpun authors: Tsoulis, Michael W.; Garcia, Victor L.; Hou, Wei; Arcan, Chrisa; Miller, Joshua D. title: Comparing body mass index and obesity‐related comorbidities as predictors in hospitalized COVID‐19 patients date: 2022-02-22 journal: Clin Obes DOI: 10.1111/cob.12514 sha: 1682bc86053b75ab9f57f5a994db53b3328e7387 doc_id: 737298 cord_uid: onnurpun The association between body mass index (BMI) and poor COVID‐19 outcomes in patients has been demonstrated across numerous studies. However, obesity‐related comorbidities have also been shown to be associated with poor outcomes. The purpose of this study was to determine whether BMI or obesity‐associated comorbidities contribute to elevated COVID‐19 severity in non‐elderly, hospitalized patients with elevated BMI (≥25 kg/m(2)). This was a single‐center, retrospective cohort study of 526 hospitalized, non‐elderly adult (aged 18–64) COVID‐19 patients with BMI ≥25 kg/m(2) in suburban New York from March 6 to May 11, 2020. The Edmonton Obesity Staging System (EOSS) was used to quantify the severity of obesity‐related comorbidities. EOSS was compared with BMI in multivariable regression analyses to predict COVID‐19 outcomes. We found that higher EOSS scores were associated with poor outcomes after demographic adjustment, unlike BMI. Specifically, patients with increased EOSS scores had increased odds of acute kidney injury (adjusted odds ratio [aOR] = 6.40; 95% CI 3.71–11.05), intensive care unit admission (aOR = 10.71; 95% CI 3.23–35.51), mechanical ventilation (aOR = 3.10; 95% CI 2.01–4.78) and mortality (aOR = 5.05; 95% CI 1.83–13.90). Obesity‐related comorbidity burden as determined by EOSS was a better predictor of poor COVID‐19 outcomes relative to BMI, suggesting that comorbidity burden may be driving risk in those hospitalized with elevated BMI. comorbidity burden quantified by higher Edmonton Obesity Staging System (EOSS) scoring was associated with worse inpatient clinical outcomes, unlike BMI alone. • This direct comparison between obesity-related comorbidity burden and BMI in patients with elevated BMI (≥25 kg/m 2 ) known to be at risk of poor COVID-19 outcomes suggests that this elevated risk is driven by obesity-related comorbidity burden, not BMI. • This study is meaningful clinically as newly admitted patients with elevated BMI without obesity-related comorbidities appear to have less severe outcomes than those with a higher obesity-related comorbidity burden. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the respiratory illness coronavirus disease 2019 , has resulted in the deaths of close to a million individuals in the United States alone. Patients with obesity, defined as body mass index (BMI) ≥30 kg/m 2 , have been identified as being at higher risk for severe COVID-19. [1] [2] [3] [4] [5] [6] Specifically, studies have shown that BMI is an independent predictor of COVID-19 severity 1,2,4-6 particularly in younger, non-elderly patients. 2, [7] [8] [9] [10] [11] [12] [13] [14] However, obesity-related comorbidities such as type 2 diabetes and hypertension have also been shown to be independent predictors of COVID-19 severity when included in studies involving BMI. 6, 9, 12, [15] [16] [17] [18] In an effort to quantify the extent of weight-related health impairment in patients with obesity, the Edmonton Obesity Staging System (EOSS) was developed in 2009 19 and has since been validated in multiple cohorts. [20] [21] [22] [23] [24] [25] [26] The EOSS is a five-stage measure of obesity based on medical, psychological and/or functional complications of obesity. 19 It effectively serves as a surrogate measure of obesity-related comorbidities and burden of disease. A comprehensive assessment of obesity-related comorbidity burden such as the EOSS in COVID-19 patients with elevated BMI would help clarify the interaction between BMI and obesity-related comorbidity burden in driving poor COVID-19 outcomes. The present study assessed the association between a modified version of EOSS and COVID-19 outcomes compared with BMI alone in a cohort of hospitalized SARS-CoV-2 infected patients with elevated BMI (≥25 kg/m 2 ) during the first surge of the pandemic in the spring of 2020. Better understanding of the interaction between BMI and obesity-related comorbidity burden will be helpful to clinicians providing anticipatory guidance to patients with COVID-19 who are known to be at increased risk of poor outcomes due to elevated BMI. Smoking status was also assessed. Patients were excluded if any of the following were met: (i) aged <18 years or ≥65 years, (ii) missing BMI or (iii) BMI <25 kg/m 2 ( Figure 1 ). Table S1 compares demographics of included and excluded patients. Physician-made diagnoses were identified either through manual chart abstraction or ICD-10 codes mapped to Clinical Classification Software (CCS) groups occurring 30 days before admission beginning January 1, 2017. Obesityrelated comorbidities were also inferred based on documented medications administered in the hospital or prescribed at discharge according to World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system and outlined in Table S2 . Specifically, if a patient had any one medication of a particular class either administered in the hospital or prescribed at discharge, that patient was classified as having been administered that medication class. Any medications routinely administered in the hospital were not F I G U R E 1 Flow chart of patients hospitalized with SARS-CoV-2 infection by EOSS stage. *Excluded patients include those with missing BMI (N = 127), BMI <25 (N = 102) included in the classification. All obesity-related comorbidities identified in prior EOSS publications 20-24 that were available in the COVID-19 Data Commons were used to classify patients according to EOSS stage using a modified staging system with three levels (stage 0, stage 1 and stage 2). Modified operational definitions of the three EOSS stages were based on previous studies. 20 In Model 1, BMI category was not associated with an increase in the odds of poor COVID-19 clinical outcomes (Table 4 ). However, in Model 2, higher EOSS stage was associated with poor COVID-19 clinical outcomes ( (Table 5 ). However, in Model 5, the EOSS total score was associated with poor COVID-19 clinical outcomes, but not mortality (Table 5) . Lastly, when both BMI and the EOSS total score were included in Model 6, the EOSS total score remained associated with poor COVID-19 clinical outcomes, but not BMI ( , has been shown to be a better prognostic factor for COVID-19 severity than its individual components including obesity. 16 However, this has been contrasted by other studies demonstrating that waist circumference alone is a better predictor relative to metabolic syndrome. 36 Despite this, other studies have also shown that the accrual of multimorbidity, 15 worse metabolic health, 37 and high comorbidity index 38 are associated with more severe COVID-19 illness. However, these studies included all-comers with BMI in the normal range and were not specific to patients with an elevated BMI. Interestingly, both median BMI and the proportion of patients in each WHO obesity class did not differ by EOSS stage. This disassociation may reflect the inadequacy of BMI to predict metabolic health. 19, 39 It may also reflect our real-world cohort consisting of those presenting with an elevated BMI from suburban New York, which likely differs from previous study cohorts. 40 [20] [21] [22] [23] [24] were able to be included (most notablyfunctional impairment secondary to obesity) as we were limited by the available data. Similarly, assessment of the correlation between laboratory data such as inflammatory markers and EOSS stage was not able to be done due to limited data availability. Similarly, we were unable to assess for socio-economic status, which has been shown to be a risk factor for COVID-19 severity and may be a mediator of the associations found in this study. 50 Lastly, our analysis does not pinpoint which particular obesity-related comorbidities contributed most to the association between EOSS stage and poor COVID-19 outcomes; future investigation with better characterized cohorts is needed in this regard. In summary, we have demonstrated that among hospitalized, Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study Body mass index and risk for severe COVID-19 among veterans health administration patients Obesity in patients with COVID-19: a systematic review and meta-analysis BMI as a risk factor for clinical outcomes in patients hospitalized with COVID-19 in New York Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization Factors associated with COVID-19-related death using OpenSAFELY Is BMI higher in younger patients with COVID-19? Association between BMI and COVID-19 hospitalization by age Predictors of worse prognosis in young and middle-aged adults hospitalized with COVID-19 pneumonia: a multi-center Italian study (COVID-UNDER50) The Association of Obesity, type 2 diabetes, and hypertension with severe coronavirus disease 2019 on admission among Mexican patients BMI and outcomes of SARS-CoV-2 among US veterans Morbid obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50 Impact of sex and metabolic comorbidities on COVID-19 mortality risk across age groups: 66,646 inpatients across 613 U.S. hospitals Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation Associations between bodymass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study Non-communicable disease, sociodemographic factors, and risk of death from infection: a UKbiobank observational cohort study. The Lancet Infect Dis Metabolic syndrome and clinical outcomes in patients infected with COVID-19: does age, sex and race of the patient with metabolic syndrome matter? The independent risk of obesity and diabetes and their interaction in COVID-19: a retrospective cohort study Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence A proposed clinical staging system for obesity Comparing the predictive ability of the Edmonton obesity staging system with the body mass index for use of health services and pharmacotherapies in Australian adults: a nationally representative cross-sectional study Edmonton obesity staging system prevalence and association with weight loss in a publicly funded referral-based obesity clinic The Edmonton obesity staging system predicts perioperative complications and procedure choice in obesity and metabolic surgery-a German Nationwide register-based cohort study (StuDoQjMBE) Using the Edmonton obesity staging system to predict mortality in a populationrepresentative cohort of people with overweight and obesity Higher Edmonton obesity staging system scores are associated with complications following laparoscopic roux-en-Y gastric bypass Edmonton obesity staging system: an improvement by cardiopulmonary exercise testing Higher Edmonton obesity staging system scores are independently associated with postoperative complications and mortality following bariatric surgery: an analysis of the MBSAQIP Stony Brook COVID-19 Research Consortium. Geospatial distribution and predictors of mortality in hospitalized patients with COVID-19: a cohort study COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) workgroup The utility of the Edmonton obesity staging system for the prediction of COVID-19 outcomes: a multi-Centre study Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death -United States The association between body mass index class and coronavirus disease 2019 outcomes The obesity paradox: analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort Obesity and COVID-19 in New York City: a retrospective cohort study Non-communicable diseases and inequalities increase risk of death among COVID-19 patients in Mexico Obesity is associated with increased risk for mortality among hospitalized patients with COVID-19 Analyses of abdominal adiposity and metabolic syndrome as risk factors for respiratory distress in COVID-19 Poor metabolic health increases COVID-19-related mortality in the UKbiobank sample Pre-existing traits associated with Covid-19 illness severity Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients The association between BMI and inpatient mortality outcomes in older adults with COVID-19 The relationship between obesity, hemoglobin A1c and the severity of COVID-19 at an urban tertiary care center Obesity and critical illness in COVID-19: respiratory pathophysiology A systematic review and metaanalysis of obesity and COVID-19 outcomes Obesity and mortality in critically ill COVID-19 patients with respiratory failure Association of body mass index with morbidity in patients hospitalised with COVID-19 The ABCD of obesity: an EASO Position Statement on a diagnostic term with clinical and scientific implications Adiposity-based chronic disease as a new diagnostic TERM: the AMERICAN association of clinical endocrinologists and AMERICAN college of ENDOCRINOLOGY POSI-TION STATEMENT Improved outcomes over time for adult COVID-19 patients with acute respiratory distress syndrome or acute respiratory failure Comparing body mass index and obesity-related comorbidities as predictors in hospitalized COVID-19 patients